Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference
23 Novembro 2021 - 10:30AM
Myovant Sciences (NYSE: MYOV), a healthcare company focused on
redefining care for women and for men, will participate in the
Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021.
David Marek, Chief Executive Officer of Myovant Sciences, Inc. will
participate in a fireside chat at 11:45 a.m. Eastern Time.
Investors and the general public are invited to listen to the
Evercore fireside chat, which will be accessible on the Events page
under the Investors & Media section of
the Myovant website at www.myovant.com.
About Myovant Sciences Myovant
Sciences aspires to redefine care for women and for men
through purpose-driven science, empowering medicines, and
transformative advocacy. Founded in 2016, Myovant has executed
five successful Phase 3 clinical trials across oncology and women’s
health leading to two regulatory approvals by the U.S. Food and
Drug Administration for men with advanced prostate cancer and women
with heavy menstrual bleeding associated with uterine fibroids,
respectively, as well as a European Commission approval for women
with symptomatic uterine fibroids. Additionally, Myovant has two
regulatory submissions under review, a Marketing Authorization
Application in advanced prostate cancer and a supplemental New Drug
Application in endometriosis-associated pain. Myovant is conducting
a Phase 3 study to evaluate the prevention of pregnancy in women
with uterine fibroids or endometriosis. Myovant is also developing
MVT-602, an investigational oligopeptide kisspeptin-1 receptor
agonist, which has completed a Phase 2a study for female
infertility as part of assisted reproduction. Sumitovant
Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon
Pharma Co., Ltd., is Myovant’s majority shareholder. For more
information, please visit www.myovant.com.
Follow @Myovant on Twitter and LinkedIn.
Investor Contact:Ryan CroweVice President,
Investor RelationsMyovant Sciences, Inc.+1 (650)
781-9106investors@myovant.com
Media Contact:Albert Liao Director,
Corporate CommunicationsMyovant Sciences, Inc.+1 (650)
410-3055media@myovant.com
Myovant Sciences (NYSE:MYOV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Myovant Sciences (NYSE:MYOV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
Notícias em tempo-real sobre Myovant Sciences Ltd da New York Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de